Skip to content
Inciteful Med

The Biology of MSA and Why It's Often Misdiagnosed

Last updated:

Multiple System Atrophy (MSA) is often misdiagnosed as Parkinson's disease because early movement symptoms are similar. Biologically, MSA is different: toxic alpha-synuclein proteins clump in brain support cells (oligodendrocytes) rather than neurons, leading to much faster disease progression.

Key Takeaways

  • • MSA and Parkinson's are both caused by the misfolding of the alpha-synuclein protein.
  • • In MSA, toxic protein clumps form in the brain's support cells (oligodendrocytes), whereas in Parkinson's, they form in neurons.
  • • The alpha-synuclein strain in MSA is far more aggressive than in Parkinson's, leading to faster disease progression.
  • • MSA is frequently misdiagnosed as Parkinson's because early symptoms like stiffness and tremors are virtually identical.
  • • Doctors differentiate MSA from Parkinson's by looking for a poor response to levodopa, early autonomic failure, and specific specialized scan results.

To understand Multiple System Atrophy (MSA), it helps to look at the brain’s biology. While MSA shares some similarities with Parkinson’s disease, the “machinery” of the disease is fundamentally different at a cellular level [1].

The Misfolding Protein: Alpha-Synuclein

Both MSA and Parkinson’s are known as synucleinopathies because they involve a protein called alpha-synuclein [1]. In a healthy brain, this protein is thought to help with communication between nerve cells. However, in MSA, this protein “misfolds”—it changes shape and begins to stick together, forming toxic clumps [1][2].

The specific “strain” of alpha-synuclein found in MSA is roughly 1,000 times more potent and aggressive at spreading than the strain found in Parkinson’s disease, which explains why MSA symptoms often progress more rapidly [3][4].

The Crucial Difference: Oligodendrocytes vs. Neurons

The biggest biological difference between these diseases is where these protein clumps accumulate:

  • In Parkinson’s Disease: Alpha-synuclein clumps (called Lewy Bodies) form mainly inside neurons, which are the cells that send electrical signals [5][6].
  • In MSA: Alpha-synuclein clumps (called Glial Cytoplasmic Inclusions or GCIs) form primarily inside oligodendrocytes [5][7].

Oligodendrocytes are the “support cells” of the brain. Their job is to create myelin, a fatty insulation that wraps around nerve fibers (axons) to help signals travel quickly [5]. When alpha-synuclein clogs these support cells, they can no longer maintain the myelin [5][8]. This leads to demyelination—the loss of that protective insulation—which eventually causes the nerve fibers themselves to wither and die [9][8].

Why Misdiagnosis is So Common

Because MSA often begins with stiffness, tremors, and balance issues, it is frequently mistaken for Parkinson’s disease in the early stages [10][11]. Doctors look for specific clues to tell them apart:

  1. Levodopa Response: Most Parkinson’s patients have a significant, long-lasting improvement in symptoms when taking levodopa (a dopamine replacement) [12]. In MSA, the response to levodopa is often poor, or it may work for a short time and then stop [13][14].
  2. Rate of Progression: MSA typically progresses much faster than Parkinson’s [15]. Patients may require walking aids or experience severe “red flag” symptoms within just a few years [16].
  3. Early Autonomic Failure: While Parkinson’s patients can have blood pressure and bladder issues, these symptoms tend to appear much earlier and much more severely in MSA [1][17].
  4. Specialized Testing: Tests like a cardiac MIBG scan can help; this scan is usually abnormal in Parkinson’s but normal in MSA, because MSA primarily damages the brain rather than the nerves surrounding the heart [12][18].

Understanding that MSA is a disease of the “support cells” helps explain why the symptoms are so widespread, affecting everything from movement to basic body functions like breathing and blood pressure [19].

Frequently Asked Questions

Why is Multiple System Atrophy often misdiagnosed as Parkinson's disease?
Early in the disease, MSA causes stiffness, tremors, and balance issues that look very similar to Parkinson's disease. It often takes time to recognize the faster progression and early autonomic symptoms that set MSA apart.
What is the biological difference between MSA and Parkinson's?
While both involve a misfolded protein called alpha-synuclein, the protein clumps in different cells. In Parkinson's, it builds up in neurons, but in MSA, it builds up in oligodendrocytes, which are the support cells that insulate nerve fibers.
Why do MSA symptoms progress faster than Parkinson's symptoms?
The specific strain of the alpha-synuclein protein found in MSA is highly aggressive and spreads much faster than the strain found in Parkinson's disease. This leads to more rapid nerve damage and worsening of symptoms.
Will levodopa help with my MSA symptoms?
While levodopa is highly effective for most Parkinson's patients, people with MSA typically have a poor response. If the medication does help initially, the benefits usually fade quickly as the disease progresses.
How can a cardiac MIBG scan help diagnose MSA?
A cardiac MIBG scan looks at the nerves surrounding the heart. In Parkinson's disease, this scan is usually abnormal, but in MSA, it is typically normal because MSA primarily damages the central brain rather than the peripheral nerves of the heart.

Questions for Your Doctor

  • • Why was I initially diagnosed with Parkinson's, and what 'red flags' eventually changed the diagnosis to MSA?
  • • Since MSA affects oligodendrocytes rather than just neurons, how does that change my treatment plan compared to a Parkinson's patient?
  • • My response to levodopa has been poor (or has faded)—is this common for the parkinsonian subtype (MSA-P)?
  • • Are my current coordination issues related to 'demyelination' in the cerebellum?
  • • Would a cardiac MIBG scan or specialized PET scan help confirm the biological differences between my condition and Parkinson's?

Questions for You

  • • How quickly have my symptoms progressed? Did I need a walking aid much sooner than I expected?
  • • Do I feel that my movement symptoms (stiffness or tremors) are actually improving with my current medications?
  • • Have I noticed any unusual sounds when I breathe at night, or has my voice become much softer or strained?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A historical review of multiple system atrophy with a critical appraisal of cellular and animal models.

    Marmion DJ, Peelaerts W, Kordower JH

    Journal of neural transmission (Vienna, Austria : 1996) 2021; (128(10)):1507-1527 doi:10.1007/s00702-021-02419-8.

    PMID: 34613484
  2. 2

    α-Synuclein: Multiple System Atrophy Prions.

    Woerman AL, Watts JC, Aoyagi A, et al.

    Cold Spring Harbor perspectives in medicine 2018; (8(7)) doi:10.1101/cshperspect.a024588.

    PMID: 28213437
  3. 3

    Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.

    Peng C, Gathagan RJ, Covell DJ, et al.

    Nature 2018; (557(7706)):558-563 doi:10.1038/s41586-018-0104-4.

    PMID: 29743672
  4. 4

    Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad.

    Reddy K, Dieriks BV

    Molecular neurodegeneration 2022; (17(1)):77 doi:10.1186/s13024-022-00579-z.

    PMID: 36435784
  5. 5

    Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology.

    Teil M, Dovero S, Bourdenx M, et al.

    Brain : a journal of neurology 2022; (145(3)):1001-1017 doi:10.1093/brain/awab374.

    PMID: 35285474
  6. 6

    In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons.

    Fouka M, Mavroeidi P, Tsaka G, Xilouri M

    Frontiers in cell and developmental biology 2020; (8()):559791 doi:10.3389/fcell.2020.559791.

    PMID: 33015057
  7. 7

    Neuropathology of Parkinson's Disease and Parkinsonism.

    Dickson DW

    Cold Spring Harbor perspectives in medicine 2025; doi:10.1101/cshperspect.a041610.

    PMID: 40324812
  8. 8

    Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease.

    Marmion DJ, Rutkowski AA, Chatterjee D, et al.

    Neurobiology of disease 2021; (148()):105184 doi:10.1016/j.nbd.2020.105184.

    PMID: 33221532
  9. 9

    Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type.

    Brettschneider J, Irwin DJ, Boluda S, et al.

    Neuropathology and applied neurobiology 2017; (43(4)):315-329 doi:10.1111/nan.12362.

    PMID: 27716988
  10. 10

    Clinical value of serum miR-451 in early diagnosis of multiple system atrophy from parkinson's disease and outcomes prediction.

    Shi T, Jia Z

    Acta neurologica Belgica 2025; doi:10.1007/s13760-025-02870-4.

    PMID: 40848180
  11. 11

    [Diagnosis of MSA-P and PSP-P in Early Stage].

    Yamawaki T

    Brain and nerve = Shinkei kenkyu no shinpo 2020; (72(4)):331-343 doi:10.11477/mf.1416201532.

    PMID: 32284458
  12. 12

    Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.

    Alves Do Rego C, Namer IJ, Marcel C, et al.

    Journal of neurology 2018; (265(9)):2033-2039 doi:10.1007/s00415-018-8941-5.

    PMID: 29956027
  13. 13

    Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

    Ye L, Sani SS, Veith Sanches L, et al.

    Brain sciences 2024; (14(10)) doi:10.3390/brainsci14100991.

    PMID: 39452005
  14. 14

    Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy.

    Miki Y, Tsushima E, Foti SC, et al.

    Brain : a journal of neurology 2021; (144(4)):1138-1151 doi:10.1093/brain/awab017.

    PMID: 33822892
  15. 15

    Multiple system atrophy: Building a global community - 30years of advocacy efforts.

    Bower PG

    Autonomic neuroscience : basic & clinical 2018; (211()):39-42 doi:10.1016/j.autneu.2017.12.006.

    PMID: 29269241
  16. 16

    A Mouse Model of Multiple System Atrophy: Bench to Bedside.

    Stefanova N

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023; (20(1)):117-126 doi:10.1007/s13311-022-01287-8.

    PMID: 35995919
  17. 17

    Autonomic nervous system dysregulation in neurodegenerative diseases: Bridging brain and heart.

    Singh S, Singh D, Ansari AH, Singh S

    Progress in brain research 2025; (294()):47-73 doi:10.1016/bs.pbr.2025.04.010.

    PMID: 40681226
  18. 18

    Cardiac 18F-Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA.

    Lenka A, Lamotte G, Goldstein DS

    Movement disorders clinical practice 2021; (8(4)):582-586 doi:10.1002/mdc3.13190.

    PMID: 33981791
  19. 19

    Neuropathology of Multiple System Atrophy, a Glioneuronal Degenerative Disease.

    Wakabayashi K, Miki Y, Tanji K, Mori F

    Cerebellum (London, England) 2024; (23(1)):2-12 doi:10.1007/s12311-022-01407-2.

    PMID: 35474048

This page explains the biology and diagnosis of Multiple System Atrophy (MSA) for educational purposes. It does not replace professional medical advice; always consult your neurologist regarding your symptoms, diagnosis, and treatment plan.

Stay up to date

Get notified when new research about Multiple system atrophy is published.

No spam. Unsubscribe anytime.